Like the autoimmune disorders above treated with rituximab, double negative IL-17+T cells, as opposed to other T cell subsets, were suppressed by approximately 50% 3 months following rituximab therapy in patients with Sjögren’s syndrome [36]. Here, IL17A is linked to Sjogren syndrome.